Stocks of Metropolis Healthcare are listed on the stock exchange on Monday The shares of the company were listed at a minimum of Rs 960 with a premium of 9.09 per cent. Investors are very happy with this. The issue price of the company shares was Rs 880.
The company's IPO was open for subscription between April 3rd and April 5th. The IPO of Rs 1,204 crore was subscribed up to 5.83 times. Metropolis Healthcare is a Dognostics Company and has two listed rivals in the market.
The company is debt-free. In the last three years from the financial year 2017-18, its net sales and net profit stood at Rs 643.5 crore and Rs 88.7 crore respectively, with annual growth of 16 per cent. Its operating margin was 27 percent in the financial year 2017-18.
The company is entering a market where competition is very much. Also many contenders in the regional market are holding their grip. Metropolis is one of the selected organized names of this market. The company started in 1981. Its reach is in 197 cities in the country.
The company strengthens its claim through 115 Clinical Labs, 1,631 Centers and 9,952 Institutional Centers. Private equity firm Carlyle is reducing its stake in the company's offer-for-sale (OFS).
In many parameters of operation it is better than Dr. Lal Pethlabs. From the financial year 2015-16, the average revenue per test has reached Rs 454 in the first nine months of the current financial year from Rs 354 to Rs 2018-19. Revenue per patient has also increased from Rs 689 to Rs 847.
For more information Top 10 Stock Advisory Company Indore
The company's IPO was open for subscription between April 3rd and April 5th. The IPO of Rs 1,204 crore was subscribed up to 5.83 times. Metropolis Healthcare is a Dognostics Company and has two listed rivals in the market.
The company is debt-free. In the last three years from the financial year 2017-18, its net sales and net profit stood at Rs 643.5 crore and Rs 88.7 crore respectively, with annual growth of 16 per cent. Its operating margin was 27 percent in the financial year 2017-18.
The company is entering a market where competition is very much. Also many contenders in the regional market are holding their grip. Metropolis is one of the selected organized names of this market. The company started in 1981. Its reach is in 197 cities in the country.
The company strengthens its claim through 115 Clinical Labs, 1,631 Centers and 9,952 Institutional Centers. Private equity firm Carlyle is reducing its stake in the company's offer-for-sale (OFS).
In many parameters of operation it is better than Dr. Lal Pethlabs. From the financial year 2015-16, the average revenue per test has reached Rs 454 in the first nine months of the current financial year from Rs 354 to Rs 2018-19. Revenue per patient has also increased from Rs 689 to Rs 847.
For more information Top 10 Stock Advisory Company Indore
0 Comments